Glycoprotein IIb/IIIa inhibitors: Difference between revisions

no edit summary
(Created page with "'''Glycoprotein IIb/IIIa inhibitors''' are antiplatelets. They are mostly used for short-term treatment before and during percutaneous coronary intervention. They are administered by i.v. injection, == Compounds == * Abciximab * Eptifibatide * Tirofiban == Mechanism of action == These drugs bind to and inhibit the receptors glycoprotein IIb/IIIa, which prevents platelets from binding to each other and therefore preventing aggregation.<noinclude>Category:Pharmaco...")
 
No edit summary
 
Line 1: Line 1:
'''Glycoprotein IIb/IIIa inhibitors''' are antiplatelets. They are mostly used for short-term treatment before and during [[percutaneous coronary intervention]]. They are administered by i.v. injection,
'''Glycoprotein IIb/IIIa inhibitors''' are [[Antiplatelet drugs|antiplatelets]]. They are mostly used for short-term treatment before and during [[percutaneous coronary intervention]]. They are administered by i.v. injection,


== Compounds ==
== Compounds ==
Line 8: Line 8:


== Mechanism of action ==
== Mechanism of action ==
These drugs bind to and inhibit the receptors glycoprotein IIb/IIIa, which prevents platelets from binding to each other and therefore preventing aggregation.<noinclude>[[Category:Pharmacology]]</noinclude>
These drugs bind to and inhibit the receptors glycoprotein IIb/IIIa, which prevents platelets from binding to each other and therefore preventing aggregation.<noinclude>
[[Category:Pharmacology]]
</noinclude>